SCHEMBL17737455

SCHEMBL17737455

CC(C)Oc1ccc(S(=O)(=O)Nc2cccc3cnccc23)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 1/20 0.55
▸ SLC40A1 Q9NP59 2/20 0.47
▸ GLO1 Q04760 1/20 0.47
▸ ALOX12 P18054 2/20 0.46
▸ FFAR4 Q5NUL3 1/20 0.46
▸ TRPV1 Q8NER1 2/20 0.46
▸ RECQL P46063 1/20 0.46
▸ CNR2 P34972 1/20 0.46
▸ DDX3X O00571 1/20 0.45
▸ KMT2A Q03164 3/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ MAPT P10636 3/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ LMNA P02545 4/20 0.44
▸ HTT P42858 2/20 0.44
▸ NAMPT P43490 2/20 0.43
▸ SQSTM1 Q13501 1/20 0.43
▸ KEAP1 Q14145 1/20 0.43
▸ NFE2L2 Q16236 1/20 0.43
▸ MITF O75030 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17737469 0.91 ALOX12 (0.56) IDO1SLC40A1GLO1ALOX12FFAR4
SCHEMBL17737442 0.87 GLO1 (0.62) IDO1SLC40A1GLO1TRPV1CNR2
SCHEMBL17737480 0.83 FFAR4 (0.46) IDO1SLC40A1FFAR4KMT2AALDH1A1
SCHEMBL17737441 0.83 IDO1 (0.62) IDO1SLC40A1GLO1ALOX12RECQL
SCHEMBL19852954 0.83 IDO1 (0.62) IDO1SLC40A1TRPV1RECQLDDX3X
SCHEMBL19852956 0.81 RECQL (0.69) IDO1SLC40A1GLO1TRPV1RECQL
SCHEMBL15452718 0.80 IDO1 (0.62) IDO1GLO1RECQLKMT2AALDH1A1
SCHEMBL17737362 0.80 IDO1 (0.62) IDO1SLC40A1ALOX12TRPV1RECQL
SCHEMBL1040890 0.80 GLO1 (0.62) IDO1GLO1TRPV1ALDH1A1HTT
SCHEMBL17737767 0.79 IDO1 (0.67) IDO1GLO1RECQLCNR2DDX3X

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3215155-B1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD (GB) 2020-10-14 — — EP disclosed
US-10287252-B2 Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase IOMET PHARMA LTD. (GB) 2019-05-14 — — US disclosed
US-20180037553-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD. (GB) 2018-02-08 — — US disclosed
WO-2016071283-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD (GB) 2016-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287252-B2 Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase TDO2, IDO2, IDO1 IDO1 3/4885SLC40A1 2382/4885GLO1 936/4885
US-20180037553-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE TDO2, IDO2, IDO1 IDO1 3/4885SLC40A1 2382/4885GLO1 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback